-
Pathology of Mantle Cell Lymphoma: Biopsies, Diagnostic Markers, and Options for Clinicians Treating This Disease
- 2023/04/27
- 再生時間: 22 分
- ポッドキャスト
-
サマリー
あらすじ・解説
Drs Peter Martin and Eric Hsi have a thought-provoking discussion on key topics in the pathology of mantle cell lymphoma, including biopsies, diagnostic markers, and what the future holds for treatment.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982892). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
College of American Pathologists https://www.cap.org
American Society of Clinical Pathology https://www.ascp.org/content
American Society of Hematology https://www.hematology.org/
Alliance for Clinical Trials in Oncology https://www.allianceforclinicaltrialsinoncology.org/main/
Diagnostic Accuracy of SOX11 Immunohistochemistry in Mantle Cell Lymphoma: A Meta-analysis https://pubmed.ncbi.nlm.nih.gov/31714947/
SOX11 Expression Is Highly Specific for Mantle Cell Lymphoma and Identifies the Cyclin D1-Negative Subtype https://pubmed.ncbi.nlm.nih.gov/19880778/
Prognostic Role of SOX11 in a Population-Based Cohort of Mantle Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/22431568/
Genomic and Epigenomic Insights Into the Origin, Pathogenesis, and Clinical Behavior of Mantle Cell Lymphoma Subtypes https://pubmed.ncbi.nlm.nih.gov/32584970/
Gastrointestinal Involvement in Patients With Mantle Cell Lymphoma: A Single Center Experience of Eighty-Five Patients https://pubmed.ncbi.nlm.nih.gov/30677768/
Incidence of Preclinical Manifestations of Mantle Cell Lymphoma and Mantle Cell Lymphoma In Situ in Reactive Lymphoid Tissues https://pubmed.ncbi.nlm.nih.gov/22790016/
PacBio https://www.pacb.com/
Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy https://pubmed.ncbi.nlm.nih.gov/32861279/
Ki67 and PIM1 Expression Predict Outcome in Mantle Cell Lymphoma Treated With High Dose Therapy, Stem Cell Transplantation and Rituximab: A Cancer and Leukemia Group B 59909 Correlative Science Study https://pubmed.ncbi.nlm.nih.gov/19021050/